ADAP stock news

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 15) AbbVie Inc (NYSE: ABBV ) Acer Therapeutics Inc (NASDAQ: ACER ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Alector Inc (NASDAQ: ALEC ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced pricing of its $6.5 million common stock offering at $1 per share) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genetic Technologies Limited (NASDAQ: GENE ) GENFIT S A/ADR (NASDAQ: GNFT ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Ironwood Pharmaceuticals, Inc. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half results and raised 2019 guidance) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 14) Acer Therapeutics Inc (NASDAQ: ACER ) (reacted to second-quarter results) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akorn, Inc. (NASDAQ: AKRX ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) aTyr Pharma Inc (NASDAQ: LIFE ) (reacted to second-quarter results) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cancer Genetics Inc (NASDAQ: CGIX ) Cellectis SA (NASDAQ: CLLS ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI )(announced $6.5 million common stock offering) DiaMedica Therapeutics Inc (NASDAQ: DMAC )(reacted to second-quarter results) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) GENFIT S A/ADR (NASDAQ: GNFT ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Medigus ADR (NASDAQ: MDGS ) Meridian Bioscience, Inc. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 12) GENMAB A/S/S ADR (NASDAQ: GMAB ) (IPOed July 1) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 13) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Advaxis, Inc. (NASDAQ: ADXS ) AnaptysBio Inc (NASDAQ: ANAB ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Hemispherx BioPharma, Inc (NYSE: HEB ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB )(reacted to second quarter results) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Mallinckrodt PLC (NYSE: MNK )(was accused by Humana Inc (NYSE: HUM ) of manipulating prices of Achtar) Mersana Therapeutics Inc (NASDAQ: MRSN ) Novavax, Inc. (NASDAQ: NVAX )(reported new data from the Phase 3 trial dubbed PREPARE that evaluated its ResVax ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Pfizer Inc. (NYSE: PFE ) Plus Therapeutics Inc (NASDAQ: PSTV ) Proteostasis … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 25) Akero Therapeutics Inc (NASDAQ: AKRO ) Anika Therapeutics Inc (NASDAQ: ANIK )( reported better-than-expected second-quarter results) Novocure Ltd (NASDAQ: NVCR )(reported strong second-quarter results) Repligen Corporation (NASDAQ: RGEN ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Baxter International Inc (NYSE: BAX ) (reacted to strong second-quarter results) West Pharmaceutical Services Inc. (NYSE: WST ) (reacted to strong second-quarter results) Myovant Sciences Ltd (NYSE: MYOV ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 25) Abeona Therapeutics Inc (NASDAQ: ABEO )(announced results from a Phase 1/2 trial of its ABO-102, its gene therapy candidate for San Filippo syndrome Type A) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP )(announced initiation of trial dubbed SPEARHEAD-1 that is evaluating ADP-A2M4 SPEAR T cells for patients with synovial sarcoma or myxoid/round cell liposarcoma) Aduro BioTech Inc (NASDAQ: ADRO ) Alkermes Plc (NASDAQ: ALKS )(reacted to Q2 results) Alterity Therapeutics Ltd (NASDAQ: ATHE ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Assembly Biosciences Inc (NASDAQ: ASMB ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) ChemoCentryx Inc (NASDAQ: CCXI ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Gamida Cell Ltd (NASDAQ: GMDA ) GENFIT S A/ADR (NASDAQ: GNFT ) Innoviva Inc (NASDAQ: INVA )(reported below-consensus second-quarter results) Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Neon Therapeutics Inc (NASDAQ: … Read more
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY )( reacted to the news of the initiation of cellulite trial) Eidos Therapeutics Inc (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 29) Abeona Therapeutics Inc (NASDAQ: ABEO ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) Allergan plc (NYSE: AGN ) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) Aptinyx Inc (NASDAQ: APTX ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) CAN-FITE BIOPHA/S ADR (NYSE: CANF )(reacted to its first-quarter results and an update on clinical trial progress) Cidara Therapeutics Inc (NASDAQ: CDTX ) Diplomat Pharmacy Inc (NYSE: DPLO ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Emergent Biosolutions Inc (NYSE: EBS ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Hookipa Pharma Inc (NASDAQ: HOOK ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Opko Health Inc. (NASDAQ: OPK ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA )( downgraded by UBS to Neutral on its legal woes) Theravance Biopharma Inc (NASDAQ: TBPH ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Unity … Read more

Adaptimmune beats by $0.27

11:36am, Monday, 06'th May 2019
Read more
- Data show strong progress with off-the-shelf program demonstrating T-cell differentiation from stem cells (hiPSC) in a serum-free process without the addition of mouse stromal cells - - Lentiviral transduction of hiPSC-derived cells with a SPEAR TCR produces transduced T-cells that can respond to cancer targets in vitro - PHILADELPHIA and OXFORDSHIRE, U.K., May 02, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ: ADAP ), a leader in T-cell therapy to treat cancer, will present new and compelling data during an oral presentation about its off-the-shelf SPEAR T-cell program at the annual American Society of Gene & Cell Therapy (ASGCT) meeting. Data indicate that T-cells can be generated from Human Induced Pluripotent Stem Cells (hiPSC) in vitro and that these T-cells respond to cancer targets via engineered SPEAR TCRs. This process will be used to investigate the ability of this off-the-shelf SPEAR T-cell product to fight cancer. "Our three autologous SPEAR T-cell therapies are already in the clinic and have the potential to treat cancer in multiple solid tumor indications," said Rafael Amado, Adaptimmune's President of R&D. "Beyond the promise of our current autologous therapies, this allogeneic approach – or more simply ‘off-the-shelf' product – could offer treatment to more patients more quickly, and provide a … Read more
Investors may be interested in following the opinion signal on shares of Adaptimmune Ther Ads (ADAP). For the current trading period, we can see that the opinion signal on the stock is 8% Sell. Headin Read more
Following shares of Adaptimmune Ther Ads (ADAP), we have noted that the Percentage Price Oscillator is currently higher than the signal line. Traders watching this indicator will be looking for signs Read more
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) making news as their share price hit $4.08 at the end of the most recent trading day. Considering that price volatility is equivalent to risk, a commodity’ Read more
Investors may be studying some short-term indicators on shares of Adaptimmune Ther Ads (ADAP). The current 7-day average directional indicator is Buy. This signal may be used to determine the market t Read more
Adaptimmune Ther Ads (ADAP)’s moving averages reveal that the Tenkan line of the shares are below the Kijun-Sen line, indicating potential downward momentum building in the bearish chart. Adaptimmun Read more

Proudly made at

ROCKIT